Why hasn't the National Institute been ‘NICE’ to patients with colorectal cancer?

por Saunders, M P, Valle, J W
Publicado 2002

Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer

por Saunders, M P, Valle, J W
Publicado 2003

Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis

por Renehan, A G, Egger, M, Saunders, M P, O'Dwyer, S T
Publicado 2005

Biomarker concordance between primary colorectal cancer and its metastases

por Bhullar, D.S., Barriuso, J., Mullamitha, S., Saunders, M.P., O'Dwyer, S.T., Aziz, O.
Publicado 2019

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

por Saunders, M P, Patterson, A V, Chinje, E C, Harris, A L, Stratford, I J
Publicado 2000

A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei

por Bibi, R, Pranesh, N, Saunders, M P, Wilson, M S, O'Dwyer, S T, Stern, P L, Renehan, A G
Publicado 2006

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

por Chinje, E C, Patterson, A V, Saunders, M P, Lockyer, S D, Harris, A L, Stratford, I J
Publicado 1999

Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy

por Duff, S E, Li, C, Jeziorska, M, Kumar, S, Saunders, M P, Sherlock, D, O'Dwyer, S T, Jayson, G C
Publicado 2003

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

por Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., Strafford, I. J.
Publicado 1997

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

por Greystoke, A, Dean, E, Saunders, M P, Cummings, J, Hughes, A, Ranson, M, Dive, C, Renehan, A G
Publicado 2012

Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study

por Sheikh, H Y, Valle, J W, Palmer, K, Sjursen, A, Craven, O, Wilson, G, Swindell, R, Saunders, M P
Publicado 2007

Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer

por Saunders, M P, Hogg, M, Carrington, B, Sjursen, A-M, Allen, J, Beech, J, Swindell, R, Valle, J W
Publicado 2004

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer

por Sheikh, H Y, Valle, J W, Waddell, T, Palmer, K, Wilson, G, Sjursen, A, Craven, O, Swindell, R, Saunders, M P
Publicado 2008

CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial

por Saunders, M.P., Graham, J., Cunningham, D., Plummer, R., Church, D., Kerr, R., Cook, S., Zheng, S., La Thangue, N., Kerr, D.
Publicado 2022

Reciprocal relationship between expression of hypoxia inducible factor 1α (HIF-1α) and the pro-apoptotic protein Bid in ex vivo colorectal cancer

por Seenath, M M, Roberts, D, Cawthorne, C, Saunders, M P, Armstrong, G R, O'Dwyer, S T, Stratford, I J, Dive, C, Renehan, A G
Publicado 2008

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

por Farquharson, A L, Pranesh, N, Witham, G, Swindell, R, Taylor, M B, Renehan, A G, Rout, S, Wilson, M S, O'Dwyer, S T, Saunders, M P
Publicado 2008

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.

por O'Byrne, K. J., Koukourakis, M. I., Saunders, M. P., Salisbury, A. J., Isaacs, R., Varcoe, S., Taylor, M., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Publicado 1998

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

por Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.
Publicado 2021

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

por Braun, M S, Adab, F, Bradley, C, McAdam, K, Thomas, G, Wadd, N J, Rea, D, Philips, R, Twelves, C, Bozzino, J, MacMillan, C, Saunders, M P, Counsell, R, Anderson, H, McDonald, A, Stewart, J, Robinson, A, Davies, S, Richards, F J, Seymour, M T
Publicado 2003

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

por Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.
Publicado 2022